Cargando…

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS

OBJECTIVE: MS is an autoimmune demyelinating disease of the CNS, which causes neurologic deficits in young adults and leads to progressive disability. The aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, can drive anti-inflammatory functions in peripheral immune cells and al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothhammer, Veit, Kenison, Jessica E., Li, Zahorong, Tjon, Emily, Takenaka, Maisa C., Chao, Chun-Cheih, Alves de Lima, Kalil, Borucki, Davis M., Kaye, Joel, Quintana, Francisco J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862099/ https://www.ncbi.nlm.nih.gov/pubmed/33408169 http://dx.doi.org/10.1212/NXI.0000000000000946

Ejemplares similares

Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and CNS inflammation via the aryl hydrocarbon receptor
por: Rothhammer, Veit, et al.
Publicado: (2016)

Detection of aryl hydrocarbon receptor agonists in human samples
por: Rothhammer, Veit, et al.
Publicado: (2018)

Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS
por: Rothhammer, Veit, et al.
Publicado: (2017)

Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS
por: Tsaktanis, Thanos, et al.
Publicado: (2020)

Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity
por: Ott, Martina, et al.
Publicado: (2019)

Astrocyte-Derived Pleiotrophin Mitigates Late-Stage Autoimmune CNS Inflammation
por: Linnerbauer, Mathias, et al.
Publicado: (2022)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation
por: Kenison, Jessica E., et al.
Publicado: (2021)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis
por: Cirac, Ana, et al.
Publicado: (2021)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor
por: Shen, Pei-Xin, et al.
Publicado: (2021)

Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis
por: Abdullah, Alzahrani, et al.
Publicado: (2019)

The aryl hydrocarbon receptor and the gut–brain axis
por: Barroso, Andreia, et al.
Publicado: (2021)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Protective Functions of Reactive Astrocytes Following Central Nervous System Insult
por: Linnerbauer, Mathias, et al.
Publicado: (2020)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Curcumin Facilitates Aryl Hydrocarbon Receptor Activation to Ameliorate Inflammatory Astrogliosis
por: Lin, Chun-Hua, et al.
Publicado: (2022)

Correction: Activation of aryl hydrocarbon receptor signaling by a novel agonist ameliorates autoimmune encephalomyelitis
Publicado: (2019)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

The Aryl Hydrocarbon Receptor as a Modulator of Anti-viral Immunity
por: Torti, Maria Florencia, et al.
Publicado: (2021)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Involvement of Aryl Hydrocarbon Receptor and Aryl Hydrocarbon Receptor Repressor in Helicobacter Pylori-related Gastric Pathogenesis
por: Zhu, Renfei, et al.
Publicado: (2018)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

Antioxidant Functions of the Aryl Hydrocarbon Receptor
por: Dietrich, Cornelia
Publicado: (2016)

Aryl Hydrocarbon Receptor and Stem Cells
por: Gasiewicz, Thomas A., et al.
Publicado: (2017)

The Aryl Hydrocarbon Receptor and Tumor Immunity
por: Xue, Ping, et al.
Publicado: (2018)

The Aryl Hydrocarbon Receptor and the Nervous System
por: Juricek, Ludmila, et al.
Publicado: (2018)

The aryl hydrocarbon receptor in liver inflammation
por: Carambia, Antonella, et al.
Publicado: (2021)

Resolving Astrocyte Heterogeneity in the CNS
por: Farmer, W. Todd, et al.
Publicado: (2017)

Aryl hydrocarbon receptor activation ameliorates experimental colitis by modulating the tolerogenic dendritic and regulatory T cell formation
por: Cui, Xiufang, et al.
Publicado: (2022)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3l84b19bhar1e0ldmvsfkpribs